BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37976417)

  • 21. FibroScan-AST (FAST) Score for Nonalcoholic Steatohepatitis - Validation in an Indian Cohort.
    De A; Keisham A; Mishra S; Mehta M; Verma N; Premkumar M; Taneja S; Das A; Singh V; Duseja A
    J Clin Exp Hepatol; 2022; 12(2):440-447. PubMed ID: 35535068
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography.
    Liang JX; Ampuero J; Niu H; Imajo K; Noureddin M; Behari J; Lee DH; Ehman RL; Rorsman F; Vessby J; Lacalle JR; Mózes FE; Pavlides M; Anstee QM; Harrison SA; Castell J; Loomba R; Romero-Gómez M;
    J Hepatol; 2023 Sep; 79(3):592-604. PubMed ID: 37121437
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of Weight Loss Interventions With Changes in Biomarkers of Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis.
    Koutoukidis DA; Astbury NM; Tudor KE; Morris E; Henry JA; Noreik M; Jebb SA; Aveyard P
    JAMA Intern Med; 2019 Sep; 179(9):1262-1271. PubMed ID: 31260026
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Women Have a Lower Risk of Nonalcoholic Fatty Liver Disease but a Higher Risk of Progression vs Men: A Systematic Review and Meta-analysis.
    Balakrishnan M; Patel P; Dunn-Valadez S; Dao C; Khan V; Ali H; El-Serag L; Hernaez R; Sisson A; Thrift AP; Liu Y; El-Serag HB; Kanwal F
    Clin Gastroenterol Hepatol; 2021 Jan; 19(1):61-71.e15. PubMed ID: 32360810
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Steatosis severity affects the diagnostic performances of noninvasive fibrosis tests in nonalcoholic fatty liver disease.
    Joo SK; Kim W; Kim D; Kim JH; Oh S; Lee KL; Chang MS; Jung YJ; So YH; Lee MS; Bae JM; Kim BG
    Liver Int; 2018 Feb; 38(2):331-341. PubMed ID: 28796410
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnostic accuracy of red blood cell distribution width to platelet ratio for predicting staging liver fibrosis in chronic liver disease patients: A systematic review and meta-analysis.
    Cai Y; Liu D; Cui J; Sha Y; Zhou H; Tang N; Wang N; Huang A; Xia J
    Medicine (Baltimore); 2019 Apr; 98(14):e15096. PubMed ID: 30946368
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Validation model of fibrosis-8 index score to predict significant fibrosis among patients with nonalcoholic fatty liver disease.
    Prasoppokakorn T; Chan WK; Wong VW; Pitisuttithum P; Mahadeva S; Nik Mustapha NR; Wong GL; Leung HH; Sripongpun P; Treeprasertsuk S
    World J Gastroenterol; 2022 Apr; 28(15):1563-1573. PubMed ID: 35582126
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis.
    Ampuero J; Pais R; Aller R; Gallego-Durán R; Crespo J; García-Monzón C; Boursier J; Vilar E; Petta S; Zheng MH; Escudero D; Calleja JL; Aspichueta P; Diago M; Rosales JM; Caballería J; Gómez-Camarero J; Lo Iacono O; Benlloch S; Albillos A; Turnes J; Banales JM; Ratziu V; Romero-Gómez M;
    Clin Gastroenterol Hepatol; 2020 Jan; 18(1):216-225.e5. PubMed ID: 31195161
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Performance of the Enhanced Liver Fibrosis Test to Estimate Advanced Fibrosis Among Patients With Nonalcoholic Fatty Liver Disease.
    Younossi ZM; Felix S; Jeffers T; Younossi E; Nader F; Pham H; Afendy A; Cable R; Racila A; Younoszai Z; Lam BP; Golabi P; Henry L; Stepanova M
    JAMA Netw Open; 2021 Sep; 4(9):e2123923. PubMed ID: 34529067
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease.
    McPherson S; Stewart SF; Henderson E; Burt AD; Day CP
    Gut; 2010 Sep; 59(9):1265-9. PubMed ID: 20801772
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care.
    Hofmann WP; Buggisch P; Schubert L; Dikopoulos N; Schwenzer J; Muche M; Felten G; Heyne R; Ingiliz P; Schmidt A; Stein K; Wedemeyer H; Berg T; Wiegand J; Lammert F; Zeuzem S; Schattenberg JM
    JHEP Rep; 2020 Dec; 2(6):100168. PubMed ID: 32964201
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis.
    Vali Y; Lee J; Boursier J; Spijker R; Löffler J; Verheij J; Brosnan MJ; Böcskei Z; Anstee QM; Bossuyt PM; Zafarmand MH;
    J Hepatol; 2020 Aug; 73(2):252-262. PubMed ID: 32275982
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis.
    Younossi ZM; Golabi P; de Avila L; Paik JM; Srishord M; Fukui N; Qiu Y; Burns L; Afendy A; Nader F
    J Hepatol; 2019 Oct; 71(4):793-801. PubMed ID: 31279902
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systematic Review with Meta-Analyses: Diagnostic Accuracy of FibroMeter Tests in Patients with Non-Alcoholic Fatty Liver Disease.
    Van Dijk AM; Vali Y; Mak AL; Lee J; Tushuizen ME; Zafarmand MH; Anstee QM; Brosnan MJ; Nieuwdorp M; Bossuyt PM; Holleboom AG
    J Clin Med; 2021 Jun; 10(13):. PubMed ID: 34209858
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of liver fibrosis using non-invasive screening tools in individuals with diabetes mellitus and metabolic syndrome.
    Shaji N; Singhai A; Joshi R
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443467
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gut microbiome-targeted therapies in nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression.
    Sharpton SR; Maraj B; Harding-Theobald E; Vittinghoff E; Terrault NA
    Am J Clin Nutr; 2019 Jul; 110(1):139-149. PubMed ID: 31124558
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical utility of serologic testing for celiac disease in ontario: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(21):1-111. PubMed ID: 23074399
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of Liver Fibrosis Using Non-invasive Screening Tools in Individuals With Diabetes Mellitus and Metabolic Syndrome.
    Shaji N; Singhai A; Sarawagi R; Pakhare AP; Mishra VN; Joshi R
    Cureus; 2022 Feb; 14(2):e22682. PubMed ID: 35386158
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Suboptimal performance of simple noninvasive tests for advanced fibrosis in Chinese patients with nonalcoholic fatty liver disease.
    Xun YH; Fan JG; Zang GQ; Liu H; Jiang YM; Xiang J; Huang Q; Shi JP
    J Dig Dis; 2012 Nov; 13(11):588-95. PubMed ID: 23107446
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.